

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER DEX-0172	
INTERNATIONAL APPLICATION NO PCT/US99/19655		INTERNATIONAL FILING DATE 1 September 1999	
TITLE OF INVENTION A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers		U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR) 09/763978	
APPLICANT(S) FOR DO/EO/US SALCEDA, Susana et al.		JC09 Rec'd PCT/PTO 2 8 FEB 2001	

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau)
 - b. ☐ has been transmitted by the International Bureau
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210)
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made, however, the time limit for making such amendments has NOT expired
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)) - **unexecuted**
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
15. ☐ A **FIRST** preliminary amendment
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- 1) Courtesy copy of International Application
- 2) Copy of Written Opinion
- 3) Return Post Card

"Express Mail" Label No. **EL853195858US**
 Date of Deposit **February 28, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
 Typed Name: Deborah Ehret

09/763978 042501

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492(a)(1) - (5)) : 09/763978		INTERNATIONAL APPLICATION NO. PCT/US99/19655		ATTORNEY'S DOCKET NUMBER DEX-0172	
---	--	--	--	---	--

21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	13 - 20 =	0	x \$18.00	\$0.00	
Independent claims	6 - 3 =	3	x \$80.00	\$240.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,100.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable) <input checked="" type="checkbox"/>				\$550.00	
SUBTOTAL =				\$550.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$550.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)) The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$550.00	
Applicant, diaDexus, Inc. is a Small Entity - Small Business Concern				Amount to be refunded	\$
				charged	\$

☐ A check in the amount of _____ to cover the above fees is enclosed
☒ **Credit Card payment form in the amount of \$550.00 for filing fee**
☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees
 A duplicate copy of this sheet is enclosed

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-1619** A duplicate copy of this sheet is enclosed

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257
 Kathleen A. Tyrrell, Reg. No. 38,350

 Licata & Tyrrell P.C.
 66 E. Main Street
 Marlton, New Jersey 08053

 Telephone: (856) 810-1515
 Facsimile : (856) 810-1454

SIGNATURE
TYRRELL, Kathleen A.
 NAME
38,350
 REGISTRATION NUMBER
28 February 2001
 DATE

09/763978
Rec'd PCT/PTO 30 APR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0172
Inventors: Salceda et al.
Serial No.: 09/763,978
Filing Date: February 28, 2001
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Various Cancers

"Express Mail" Label No. EV104364675US
Date of Deposit - April 30, 2002

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the U.S. Patent and
Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202

By


Typed Name: Kathleen A. Tyrrell

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202


Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- () I hereby state, in accordance with the requirements of 37
C.F.R. §1.821(f), that the contents of the paper and
computer readable copies of the Sequence Listing, submitted
in accordance with 37 CFR §1.821(c) and (e), respectively
are the same.
- () I hereby state that the submission filed in accordance with
37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- (XX) I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: April 30, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

04763408 042503
Rec'd PCT/PTO

01 FEB 2001

WO 00/12758

PCT/US99/19655

A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating various cancers,
particularly gynecologic cancer including ovarian, uterine
endometrial and breast cancer, and lung cancer.

BACKGROUND OF THE INVENTION

10 The American Cancer Society has estimated that over
560,000 Americans will die this year from cancer. Cancer is
the second leading cause of death in the United States,
exceeded only by heart disease. It has been estimated that
over one million new cancer cases will be diagnosed in 1999
15 alone.

In women, gynecologic cancers account for more than one-
fourth of the malignancies.

Of the gynecologic cancers, breast cancer is the most
common. According to the Women's Cancer Network, 1 out of
20 every 8 women in the United States is at risk of developing
breast cancer, and 1 out of every 28 women are at risk of
dying from breast cancer. Approximately 77% of women
diagnosed with breast cancer are over the age of 50.
However, breast cancer is the leading cause of death in women
25 between the ages of 40 and 55.

Carcinoma of the ovary is another very common
gynecologic cancer. Approximately one in 70 women will
develop ovarian cancer during her lifetime. An estimated
14,500 deaths in 1995 resulted from ovarian cancer. It causes
30 more deaths than any other cancer of the female reproductive
system. Ovarian cancer often does not cause any noticeable

- 2 -

symptoms. Some possible warning signals, however, are an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40; rarely there will be abnormal vaginal bleeding. Periodic, complete pelvic examinations are important; a Pap test does not detect ovarian cancer. Annual pelvic exams are recommended for women over 40.

Also common in women is endometrial cancer or carcinoma of the lining of the uterus. According to the Women's Cancer Center endometrial cancer accounts for approximately 13% of all malignancies in women. There are about 34,000 cases of endometrial cancer diagnosed in the United States each year.

Uterine sarcoma is another type of uterine malignancy much more rare as compared to other gynecologic cancers. In uterine sarcoma, malignant cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. This uterine cancer usually begins after menopause. Women who have received therapy with high-dose X-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These X-rays are sometimes given to women to stop bleeding from the uterus.

Lung cancer is the second most prevalent type of cancer for both men and women in the United States and is the most common cause of cancer death in both sexes. Lung cancer can result from a primary tumor originating in the lung or a secondary tumor which has spread from another organ such as the bowel or breast. Primary lung cancer is divided into three main types; small cell lung cancer; non-small cell lung cancer; and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer. These are grouped together because they behave in a similar way and respond to treatment differently to small

- 3 -

cell lung cancer. The three types are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma
5 also develops from the cells that line the airways. However, adenocarcinoma develops from a particular type of cell that produces mucus (phlegm). Large cell lung cancer has been thus named because the cells look large and rounded when they are viewed under a microscope. Mesothelioma is a rare type of
10 cancer which affects the covering of the lung called the pleura. Mesothelioma is often caused by exposure to asbestos.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating each of these types of cancer are of critical importance to the outcome of the patient. In all
15 cases, patients diagnosed early in development of the cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with a cancer which has metastasized. New diagnostic methods which are more sensitive and specific for early detection of various
20 types of cancer are clearly needed.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating selected cancers including, but not limited to, gynecologic cancers such as ovarian, breast
25 endometrial and/or uterine cancer, and lung cancer via detection of a Cancer Specific Genes (CSGs). Nine CGSs have been identified and refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9.
30 In the alternative, what is meant by the nine CSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4,

- 4 -

5, 6, 7, 8 or 9. Fragments of the CSGs such as those depicted in SEQ ID NO:10, 11, 12, 13 or 14 can also be detected.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the selected cancer. For the purposes of this invention, by "selected cancer" it is meant to include gynecologic cancers such as ovarian, breast, endometrial and uterine cancer, and lung cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having a selected cancer which is not known to have metastasized by identifying a human patient suspected of having a selected cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient

- 5 -

versus the normal human control is associated with a cancer which has metastasized.

Also provided by the invention is a method of staging selected cancers in a human patient by identifying a human
5 patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in
10 CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring selected
15 cancers in patients for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or
20 bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change
25 in stage of selected cancers in humans having such cancer by looking at levels of CSG. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from
30 such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a
35 cancer which is progressing and a decrease in the levels of

CSG is associated with a cancer which is regressing or in remission.

Further provided are antibodies against CSG or fragments of such antibodies which can be used to detect or image localization of CSG in a patient for the purpose of detecting or diagnosing selected cancers. Such antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating selected

- 7 -

cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein is levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by levels of CSG as used herein is levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the gene comprising any of the polynucleotide sequences of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8 or 9. Fragments of CSGs such as those depicted in SEQ ID NO: 10, 11, 12, 13 and 14 can also be detected. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of CSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of selected cancers. What is meant by "selected cancers" as used herein is a gynecologic cancer such as ovarian, breast, endometrial or uterine cancer, or lung case.

Any of the 9 CSGs can be measured alone in the methods of the invention, or all together or any combination thereof. However, for methods relating to gynecologic cancers including ovarian, breast, endometrial and uterine cancer, it is preferred that levels of CSG comprising SEQ ID NO:1 or a fragment thereof be determined. Exemplary fragments of this CSG which can be detected are depicted in SEQ ID NO: 10, 11, 12, and 13. For methods relating to lung cancer and gynecologic cancers including ovarian, endometrial and uterine, it is preferred that levels of CSG comprising SEQ ID NO:2 or 9 be determined. Fragments of this CSG such as that depicted in SEQ ID NO:14 can also be detected. For methods relating to ovarian cancer, determination of levels of CSG comprising SEQ ID NO:3 is also preferred.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested
5 and are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with
10 levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the presence of a selected cancer.

Without limiting the instant invention, typically, for
15 a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells,
20 tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastases of selected cancers in a patient having a selected cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a
25 human cancer patient suspected of having a selected cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of ovarian cancer, patients
30 are typically diagnosed with ovarian cancer following surgical staging and monitoring of CA125 levels. Traditional detection methods are also available and well known for other selected cancers which can be diagnosed by determination of CSG levels in a patient.

In the present invention, determining the presence of CSG levels in cells, tissues or bodily fluid, is particularly useful for discriminating between a selected cancer which has not metastasized and a selected cancer which has metastasized.

5 Existing techniques have difficulty discriminating between cancers which have metastasized and cancers which have not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels
10 measured in such cells, tissues or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CSG in serum, this level is preferably compared with the level of CSG in serum
15 of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating
20 the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily
25 fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may also include samples from
30 a human patient that is determined by reliable methods to have a selected cancer which has not metastasized.

Staging

The invention also provides a method of staging selected cancers in human patients. The method comprises identifying
35 a human patient having a selected cancer and analyzing a

- 10 -

sample of cells, tissues or bodily fluid from such human patient for CSG. Then, the method compares CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

10 **Monitoring**

Further provided is a method of monitoring selected cancers in humans for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of selected cancers in humans having such cancers. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission.

- 11 -

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

5 **Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include
10 radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein
15 in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds
20 specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is
25 incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds
30 to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG.
35 Unattached reporter antibody is then washed out. Reagents for

- 12 -

peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to CSG attached to a solid support and labeled CSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as a marker for selected cancers. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of the various selected malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon

- 13 -

or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

5 Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be
10 done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

15 Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.
20 First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on
25 the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or
30 subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue
35 extracts (homogenates or solubilized tissue) such as from

- 14 -

tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.

5 ***In Vivo Antibody Use***

Antibodies against CSG can also be used *in vivo* in patients suspected of suffering from a selected cancer including lung cancer or gynecologic cancers such as ovarian, breast, endometrial or uterine cancer. Specifically,
10 antibodies against a CSG can be injected into a patient suspected of having a selected cancer for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use
15 in the radioimmunoscentigraphic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin.
20 Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in a similar manner. Labeled antibodies against a CSG can be
25 injected into patients suspected of having a selected cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or
30 Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can used in magnetic resonance imaging (MRI).
35 Localization of the label permits determination of the spread

- 15 -

of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with a selected cancer, injection
5 of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been
10 described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have
15 been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of
20 antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded
25 oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

The present invention is further described by the following examples. These examples are provided solely to
30 illustrate the invention by reference to specific embodiments. The exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

EXAMPLES**Example 1:**

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease. Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

Table 1: CSG Sequences

	SEQ ID NO:	Clone ID	Gene ID
	1	16656542	234617
	2	1283171	332459
	3	1649377	481154
25	4	236044H1	none assigned
	5	none assigned	255687
	6	none assigned	251313
	7	none assigned	12029
	8	none assigned	251804

30

The following examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail.

- 17 -

Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene for every example in normal and cancer tissue were evaluated. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700

- 18 -

Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Measurement of Ovr110; Clone ID16656542; Gene ID 234617 (SEQ ID NO:1, 10, 11, 12 or 13)

The absolute numbers depicted in Table 2 are relative levels of expression of Ovr110 (SEQ ID NO:1 or a fragment thereof as depicted in SEQ ID NO:10, 11, 12, or 13) in 12 normal different tissues. All the values are compared to normal stomach (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 2: Relative Levels of Ovr110 Expression in Pooled Samples

Tissue	NORMAL
colon	0.00
endometrium	8.82
kidney	7.19
liver	0.36
ovary	1.19
pancreas	21.41
prostate	2.79
small intestine	0.03
spleen	0.00
00000000000000stoma	1.00
testis	8.72
uterus	0.93

The relative levels of expression in Table 2 show that Ovr110 is expressed at comparable levels in most of the normal tissues analyzed. Pancreas, with a relative expression level of 21.41, endometrium (8.82), testis (8.72), and kidney (7.19) are the only tissues expressing high levels of Ovr110 mRNA.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Ovr110 in 73 pairs of matching samples. All the values are compared to normal stomach (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 15 unmatched cancer samples (from ovary and mammary gland) and 14 unmatched normal samples (from ovary and mammary gland) were also tested.

10 **Table 3: Relative Levels of Ovr110 Expression in Individual Samples**

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
Ovr103X	Ovary 1	86.22	0.53	
Ovr10400	Ovary 2	168.31		
15 Ovr1157	Ovary 3	528.22		
Ovr63A	Ovary 4	1.71		
Ovr7730	Ovary 5	464.65		
Ovr10050	Ovary 6	18.32		
Ovr1028	Ovary 7	7.78		
20 Ovr1118	Ovary 8	0.00		
Ovr130X	Ovary 9	149.09		
Ovr638A	Ovary 10	3.14		
OvrA1B	Ovary 11	21.26		
OvrA1C	Ovary 12	1.83		
25 OvrC360	Ovary 13	0.52		
Ovr18GA	Ovary 14			1.07
Ovr20GA	Ovary 15			1.88
Ovr25GA	Ovary 16			2.52
Ovr206I	Ovary 17			2.51
30 Ovr32RA	Ovary 18			3.01

WO 00/12758

PCT/US99/19655

- 20 -

5	Ovr35GA	Ovary 19			5.17
	Ovr40G	Ovary 20			0.45
	Ovr50GB	Ovary 21			2.69
	OvrC087	Ovary 22			0.47
	OvrC179	Ovary 23			1.46
	OvrC004	Ovary 24			4.99
	OvrC007	Ovary 25			13.36
	OvrC109	Ovary 26			6.61
10	MamS516	Mammary Gland 1	16.39	13.74	
	MamS621	Mammary Gland 2	826.70	4.60	
	MamS854	Mammary Gland 3	34.60	18.30	
	Mam59X	Mammary Gland 4	721.57	27.00	
	MamS079	Mammary Gland 5	80.73	5.10	
15	MamS967	Mammary Gland 6	6746.90	72.80	
	MamS127	Mammary Gland 7	7.00	20.00	
	MamB011X	Mammary Gland 8	1042.00	29.00	
	Mam12B	Mammary Gland 9	1342.00		
	Mam82XI	Mammary Gland 10	507.00		
20	MamS123	Mammary Gland 11	24.85	4.24	
	MamS699	Mammary Gland 12	84.74	5.54	
	MamS997	Mammary Gland 13	482.71	11.84	
	Mam162X	Mammary Gland 14	15.73	10.59	

WO 00/12758

PCT/US99/19655

- 21 -

	MamA06X	Mammary Gland 15	1418.35	8.20	
	Mam603X	Mammary Gland 16	294.00		
	Mam699F	Mammary Gland 17	567.40	86.60	
	Mam12X	Mammary Gland 18	425.00	31.00	
5	MamA04	Mammary Gland 19			2.00
	Mam42DN	Mammary Gland 20	46.05	31.02	
	Utr23XU	Uterus 1	600.49	27.95	
	Utr85XU	Uterus 2	73.52	18.83	
	Utr135XO	Uterus 3	178.00	274.00	
10	Utr141XO	Uterus 4	289.00	26.00	
	CvxNKS54	Cervix 1	2.47	0.61	
	CvxKS83	Cervix 2	1.00	2.00	
	CvxNKS18	Cervix 3	1.00	0.00	
	CvxNK23	Cervix 4	5.84	14.47	
15	CvxNK24	Cervix 5	20.32	33.13	
	End68X	Endometrium 1	167.73	544.96	
	End8963	Endometrium 2	340.14	20.89	
	End8XA	Endometrium 3	1.68	224.41	
	End65RA	Endometrium 4	303.00	5.00	
20	End8911	Endometrium 5	1038.00	74.00	
	End3AX	Endometrium 6	6.59	1.69	
	End4XA	Endometrium 7	0.43	15.45	

WO 00/12758

PCT/US99/19655

- 22 -

5	End5XA	Endometrium 8	17.81	388.02	
	End10479	Endometrium 9	1251.60	31.10	
	End12XA	Endometrium 10	312.80	33.80	
	Kid107XD	Kidney 1	2.68	29.65	
	Kid109XD	Kidney 2	81.01	228.33	
10	Kid10XD	Kidney 3	0.00	15.30	
	Kid6XD	Kidney 4	18.32	9.06	
	Kid11XD	Kidney 5	1.38	20.75	
	Kid5XD	Kidney 6	30.27	0.19	
	Liv15XA	Liver 1	0.00	0.45	
15	Liv42X	Liver 2	0.81	0.40	
	Liv94XA	Liver 3	12.00	2.16	
	Lng LC71	Lung 1	5.45	3.31	
	LngAC39	Lung 2	1.11	0.00	
	LngBR94	Lung 3	4.50	0.00	
20	LngSQ45	Lung 4	15.03	0.76	
	LngC20X	Lung 5	0.00	1.65	
	LngSQ56	Lung 6	91.77	8.03	
	ClnAS89	Colon 1	0.79	7.65	
	ClnC9XR	Colon 2	0.03	0.00	
25	ClnRC67	Colon 3	0.00	0.00	
	ClnSG36	Colon 4	0.81	0.35	
	ClnTX89	Colon 5	0.00	0.00	
	ClnSG45	Colon 6	0.00	0.06	
	ClnTX01	Colon 7	0.00	0.00	
	Pan77X	Pancreas 1	0.89	2.62	
	Pan71XL	Pancreas 2	3.99	0.12	
	Pan82XP	Pancreas 3	59.92	28.44	
	Pan92X	Pancreas 4	17.21	0.00	

	StoAC93	Stomach 1	7.54	6.43	
	StoAC99	Stomach 2	19.49	3.19	
	StoAC44	Stomach 3	3.62	0.37	
	SmI21XA	Small Intestine 1	0.00	0.00	
5	SmIH89	Small Intestine 2	0.00	0.00	
	Bld32XK	Bladder 1	0.00	0.21	
	Bld46XK	Bladder 2	0.36	0.32	
	BldTR17	Bladder 3	0.28	0.00	
	Tst39X	Testis	11.24	2.24	
10	Pro84XB	Prostate 1	2.60	24.30	
	Pro90XB	Prostate 2	1.40	2.00	

0.00= Negative

Table 2 and Table 3 represent a combined total of 187 samples in 16 different tissue types. In the analysis of matching samples, the higher levels of expression were in mammary gland, uterus, endometrium and ovary, showing a high degree of tissue specificity for the gynecologic tissues. Of all the samples different than those mentioned before analyzed, only a few samples (Kid109XD, LngSQ56, and Pan82XP) showed high levels of expression of Ovr110.

Furthermore, the level of mRNA expression was compared in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Ovr110 in 15 of 16 mammary gland cancer tissues compared with their respective normal adjacent (mammary gland samples MamS516, MamS621, MamS854, Mam59X, MamS079, MamS967, MamB011X, MamS123, MamS699, MamS997, Mam162X, MamA06X, Mam699F, Mam12X, and Mam42DN).

- 24 -

There was overexpression in the cancer tissue for 94% of the mammary gland matching samples tested.

For uterus, Ovr110 is overexpressed in 3 of 4 matching samples (uterus samples Utr23XU, Utr85XU, and Utr141XO). There
5 was overexpression in the cancer tissue for 75% of the uterus matching samples analyzed.

For endometrium, Ovr110 is overexpressed in 6 of 10 matching samples (endometrium samples End8963, End65RA, End8911, End3AX, End10479, and End12XA). There was
10 overexpression in the cancer tissue for 60% of the endometrium matching samples.

For ovary, Ovr110 shows overexpression in 1 of 1 matching sample. For the unmatched ovarian samples, 8 of 12 cancer samples show expression values of Ovr110 higher than
15 the median (2.52) for the normal unmatched ovarian samples. There was overexpression in the cancer tissue for 67% of the unmatched ovarian samples.

Altogether, the level of tissue specificity, plus the mRNA overexpression in most of the matching samples tested are
20 indicative of Ovr110 (including SEQ ID NO:1, 10, 11, 12 or 13) being a diagnostic marker for gynecologic cancers, specifically, mammary gland or breast, uterine, ovarian and endometrial cancer.

**Measurement of Ovr114; Clone ID1649377; Gene ID 481154 (SEQ
25 ID NO:3)**

The numbers depicted in Table 4 are relative levels of expression in 12 normal tissues of Ovr114 compared to pancreas (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue
30 from different individuals.

Table 4: Relative Levels of Ovr114 Expression in Pooled Samples

	Tissue	Normal
5	Colon	2.3
	Endometrium	7.6
	Kidney	0.5
	Liver	0.6
	Ovary	5.2
	Pancreas	1.0
10	Prostate	2.1
	Small Intestine	1.3
	Spleen	2.4
	Stomach	1.5
	Testis	15.8
15	Uterus	8.8

The relative levels of expression in Table 4 show that Ovr114 mRNA expression is detected in all the pools of normal tissues analyzed.

The tissues shown in Table 4 are pooled samples from 20 different individuals. The tissues shown in Table 5 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 4 cannot be directly compared to the values shown in Table 5.

The numbers depicted in Table 5 are relative levels of 25 expression of Ovr114 compared to pancreas (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 5: Relative Levels of Ovr114 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	17.04		3.93
Ovary 2	OvrG021SPI/SN2	Papillary serous adenocarcinoma	1.62		4.34
Ovary 3	OvrG010SP/SN	Papillary serous adenocarcinoma	0.50		1.12
Ovary 4	OvrA081F/A082D	Mucinous tumor, low malignant potential		0.84	0.96
Ovary 5	OvrA084/A086	Mucinous tumor, grade G-B, borderline		5.24	6.00
Ovary 6	Ovr14604A1C	Serous cystadenofibroma, low malignancy		5.33	
Ovary 7	Ovr14638A1C	Follicular cysts, low malignant potential		8.11	
Ovary 8	Ovr10400	Papillary serous adenocarcinoma, G2	13.27		
Ovary 9	Ovr11570	Papillary serous adenocarcinoma	106.08		
Ovary 10	Ovr10050	Papillary serous endometrioid carcinoma	77.04		
Ovary 11	Ovr10280	Ovarian carcinoma	14.78		
Ovary 12	Ovr14603A1D	Adenocarcinoma	22.23		

- 27 -

Ovary 13	Ovr9410C360	Endometrioid adenocarcinoma	4.74		
Ovary 14	Ovr1305X	Papillary serous adenocarcinoma	96.49		
Ovary 15	Ovr7730	Papillary serous adenocarcinoma	8.40		
Ovary 16	Ovr988Z	Papillary serous adenocarcinoma	6.40		
Ovary 17	Ovr9702C018GA	Normal Cystic			12.06
Ovary 18	Ovr2061	Normal left atrophic, small cystic			10.11
Ovary 19	Ovr9702C020GA	Normal-multiple ovarian cysts			12.70
Ovary 20	Ovr9702C025GA	Normal-hemorrhage CL cysts			22.09
Ovary 21	Ovr9701C050GB	Normal-multiple ovarian cysts			9.01
Ovary 22	Ovr9701C087RA	Normal-small follicle cysts			1.86
Ovary 23	Ovr9702C032RA				7.81
Ovary 24	Ovr9701C109RA	Normal			1.50
Ovary 25	Ovr9411C057R	Benign large endometriotic cyst			5.22
Ovary 26	Ovr9701C179a	Normal			3.09
Ovary 27	Ovr14610	Serous cystadenofibroma, no malignancy			3.53
Ovary 28	Ovr9701C035GA	Normal			6.32

5

10.

15

- 28 -

Ovary 29	Ovr9702C007RA	Normal			0
Ovary 30	Ovr9701C087RA	Normal-small follicle cysts			1.97
Ovary 31	Ovr9411C109	Normal			9.49
Ovary 32	Ovr9701C177a	Normal-cystic follicles			3.85
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	1.30		0.70
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	1.83		11.90
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	13.32		7.76
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	3.62		3.34
Mammary Gland 1	Mam00042D01/N01		3.13		0.76
Mammary Gland 2	MamS99-522A/B		4.45		0.45
Mammary Gland 3	Mam1620F/1621F		0.74		1.91
Mammary Gland 4	Mam4003259a/g		3.48		2.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	46.96		11.96
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	20.02		5.90
Uterus 3	Utr1359O/1358O	Tumor/NAT	10.23		7.74
Uterus 4	Utr1417O/1418O	Malignant tumor/NAT	7.52		4.92

5

10

15

20

- 29 -

Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma	5.47		14.31
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	4.99		3.99
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	10.14		14.22
Bladder 1	Bld665T/664T		1.43		4.03
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	1.15		0.99
Kidney 1	Kid4003710C/F		0.03		0.35
Kidney 2	Kid1242D/1243D		1.61		0.14
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	2.44		5.73
Lung 2	Lng8890A/8890B	Cancer/NAT	1.11		5.19
Lung 3	Lng9502C109R/10R		1.99		0.80
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.67		1.07
Liver 2	LivVNM00175/175	Cancer/NAT	15.46		2.85
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	2.83		0.70
Skin 2	Skn4005287A1/B2		0.91		4.02
Small Int. 1	SmI9802H008/009		0.87		0.82
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	0.81		1.22
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT	1.22		1.39

5

10

15

Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.47		0.35
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	2.39		2.61
Prostate 2	Pro1094B/1095B		0.10		0.38
Pancreas 1	Pan776p/777p	Tumor/NAT	2.39		0.52
Pancreas 2	Pan824p/825p	Cystic adenoma	1.66		1.22
Testis 1	Tst239X/240X	Tumor/NAT	1.24		1.72
Colon 1	ClN9706c068ra/69 ra	Adenocarcinoma/NAT	0.38		0.65
Colon 2	ClN4004732A7/B6	Adenocarcinoma/NAT	0.44		1.26
Colon 3	ClN4004695A9/B8		1.94		1.53
Colon 4	ClN9612B006/005	Asc. Colon, Cecum, adenocarcinoma	3.38		1.10
Colon 5	ClN9704C024R/25R	Adenocarcinoma/NAT	1.66		2.77

- 31 -

Table 4 and Table 5 represent a combined total of 129 samples in 17 human tissue types. Among 117 samples in Table 5 representing 16 different tissues high levels of expression are seen only in ovarian cancer samples. The median expression of Ovr114 is 14.03 (range: 0.5 - 106.08) in ovarian cancer and 4.34 (range: 0 - 22.09) in normal ovaries. In other words, the median expression levels of Ovr114 in cancer samples is increased 3.5 fold as compared with that of the normal ovarian samples. Five of 12 ovarian cancers (42%) showed increased expression relative to normal ovary (with 95% specificity). The median expression of Ovr114 in other gynecologic cancers is 4.99, and 2 out of 15 samples showed expression levels comparable with that in ovarian cancer. The median of the expression levels of Ovr114 in the rest of the cancer samples is 1.24, which is more than 11 fold less than that detected in ovarian cancer samples. No individual showed an expression level comparable to that of ovarian cancer samples (except Liver 2; LivVNM00175/175).

The 3.5 fold increase in expression in 42% of the individual ovarian cancer samples and no compatible expression in other non-gynecologic cancers is indicative of Ovr114 being a diagnostic marker for detection of ovarian cancer cells. It is believed that the Ovr114 marker may also be useful in detection of additional gynecologic cancers.

Measurement of Ovr115; Clone ID1283171; Gene ID 332459 (SEQ ID NO:2 or 14)

The numbers depicted in Table 6 are relative levels of expression Ovr115 compared to their respective calibrators. The numbers are relative levels of expression in 12 normal tissues of ovaries compared to Testis (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

- 32 -

Table 6: Relative Levels of Ovr115 Expression in Pooled Samples

Tissue	Normal
Colon	858.10
Endometrium	12.34
Kidney	3.76
Liver	0.00
Ovary	0.43
Pancreas	0.00
Prostate	8.91
Small Intestine	62.25
Spleen	0.00
Stomach	37.53
Testis	1.00
Uterus	47.67

The relative levels of expression in Table 6 show that Ovr115 mRNA expression is detected in all the 12 normal tissue pools analyzed.

The tissues shown in Table 6 are pooled samples from different individuals. The tissues shown in Table 7 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 6 cannot be directly compared to the values shown in Table 7.

The numbers depicted in Table 7 are relative levels of expression of Ovr115 compared to testis (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 7: Relative Levels of Ovr115 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	193.34		0.24
Ovary 3	OvrG021SPI/SN2	Papillary serous adenocarcinoma	0.38		0.31
Ovary 4	OvrG010SP/SN	Papillary serous adenocarcinoma	231.25		0.45
Ovary 2	OvrA084/A086	Mucinous tumor, grade G-B, borderline		143.34	16.65
Ovary 5	OvrA081F/A082D	Mucinous tumor, low malignant potential		314.13	0
Ovary 19	Ovr14604A1C	Serous cystadenofibroma, low malignancy		299.87	
Ovary 26	Ovr14638A1C	Follicular cysts, low malignant potential		1278.32	
Ovary 6	Ovr10400	Papillary serous adenocarcinoma, G2	144.25		
Ovary 22	Ovr9410C360	Endometrioid adenocarcinoma	0.29		
Ovary 23	Ovr1305X	Papillary serous adenocarcinoma	157.41		
Ovary 27	Ovr7730	Papillary serous adenocarcinoma	340.04		
Ovary 28	Ovr988Z	Papillary serous adenocarcinoma	464.75		

- 34 -

Ovary 7	Ovr11570	Papillary serous adenocarcinoma	432.07		
Ovary 8	Ovr10050	Papillary serous endometrioid carcinoma	74.23		
Ovary 9	Ovr10280	Ovarian carcinoma	1408.79		
Ovary 10	Ovr14603A1D	Adenocarcinoma	0.00		
Ovary 11	Ovr9702C018GA	Normal Cystic			0.16
Ovary 12	Ovr2061	Normal left atrophic, small cystic			0.00
Ovary 13	Ovr9702C020GA	Normal-multiple ovarian cysts			0.00
Ovary 14	Ovr9702C025GA	Normal-hemorrhage CL cysts			0.00
Ovary 15	Ovr9701C050GB	Normal-multiple ovarian cysts			0.91
Ovary 16	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 17	Ovr9702C032RA				0.28
Ovary 18	Ovr9701C109RA	Normal			0.00
Ovary 20	Ovr9411C057R	Benign large endometrioid cyst			38.87
Ovary 21	Ovr9701C179a	Normal			0.08
Ovary 24	Ovr14610	Serous cystadenofibroma, no malignancy			0.00
Ovary 25	Ovr9701C035GA	Normal			0.00
Ovary 29	Ovr9702C007RA	Normal			0.00

5

10

15

Ovary 30	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 31	Ovr9411C109	Normal			0.00
Ovary 32	Ovr9701C177a	Normal-cystic follicles			0.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	39.95		13.60
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	140.37		22.67
Uterus 3	Utr1359O/1358)	Tumor/NAT	16.45		32.50
Uterus 4	Utr1417O/1418O	Malignant tumor/NAT	288.52		5.29
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	2.61		6.24
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	2.10		49.40
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	480.77		19.22
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	322.07		31.08
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	38.81		7.36
Lung 2	Lng8890A/8890B	Cancer/NAT	690.12		14.71
Lung 3	Lng9502C109R/10R		1756.90		2.86
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	10.56		0.00
Skin 2	Skn4005287A1/B2		331.30		47.23
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	14.64		4.39

5

10

15

Prostate 2	Pro1094B/1095B		0.09		2.54
Bladder 1	Bld665T/664T		404.56		90.20
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	77.35		177.37
Kidney 1	Kid4003710C/F		0.17		12.72
Kidney 2	Kid1242D/1243D		0.00		13.74
Mammary Gland 1	Mam1620F/1621F		0.27		0.12
Mammary Gland 2	Mam4003259a/g		5.71		0.00
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.14		0.69
Liver 2	LivVNM00175/175	Cancer/NAT	0.00		0.00
Small Int. 1	SmI9802H008/009		128.44		151.38
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	303.01		116.72
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT	24.12		17.76
Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.00		9.10
Pancreas 1	Pan776p/777p	Tumor/NAT	0.00		0.43
Pancreas 2	Pan824p/825p	Cystic adenoma	0.00		3.17
Testis 1	Tst239X/240X	Tumor/NAT	24.05		1.37
Colon 1	ClN9706c068ra/69ra	Adenocarcinoma/NAT	605.60		169.77
Colon 2	ClN4004732A7/B6	Adenocarcinoma/NAT	367.20		281.32

5

10

15

20

Colon 3	Cln4004695A9/B8			316.15		295.77
Colon 4	Cln9612B006/005	Asc. Colon. Cecum, adenocarcinoma		820.89		543.52
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT		161.18		150.07
Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma		738.17		1195.88
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma		1473.04		1229.80
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma		2877.48		1275.02

- 38 -

Table 6 and Table 7 represent a combined total of 129 samples in 17 human tissue types. Comparisons of the level of mRNA expression in ovarian cancer samples and the normal adjacent tissue from the same individuals or normal tissues from other individuals are shown in Table 7. Ovr115 was expressed at higher levels in 9 of 12 cancer tissues (75%), relative to the maximum level detected in all 21 normal or normal adjacent ovarian samples. All 4 of 4 (100%) ovarian tumors with borderline malignancy had elevated Ovr115 expression. The median expression in ovarian cancers (including the ones with borderline malignancy) was 212.30 while the median expression in normal ovaries was 0. When compared with their own normal adjacent tissue samples, expression levels of Ovr115 were also elevated in 3 of 3 (100%) lung cancers, 3 of 4 (75%) uterus cancers and 2 of 4 (50%) endometrial cancers.

The relatively high expression levels of Ovr115 in ovarian and other selected cancer samples is indicative of Ovr115 being a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer.

A homolog of Ovr115 has also been identified in public data base; g2597613 as gi|2507612|gb|U75329.1|HSU75329 Human serine protease mRNA, complete CDS. This homolog is depicted herein as SEQ ID NO:9. It is believed that SEQ ID NO:9 or the protein encoded thereby (SEQ ID NO:15) may also be useful as a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer in human patients.

- 39 -

What is claimed is:

1. A method for diagnosing the presence of a selected cancer in a patient comprising:

(a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and

5 (b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of a selected cancer.

10 2. A method of diagnosing metastases of a selected cancer in a patient comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) measuring CSG levels in a sample of cells, tissues,
15 or bodily fluid from said patient; and

(c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer
20 which has metastasized.

3. A method of staging a selected cancer in a patient having the selected cancer comprising:

(a) identifying a patient having the selected cancer;

(b) measuring CSG levels in a sample of cells, tissue,
25 or bodily fluid from said patient; and

(c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a
30 cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

- 40 -

4. A method of monitoring a selected cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) periodically measuring levels of CSG in samples of
5 cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the
10 normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of a selected cancer in a patient comprising:

(a) identifying a patient having a selected cancer;

15 (b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the
20 periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG
25 comprises SEQ ID NO:1, 10, 11, 12 or 13 and the selected cancer is a gynecologic cancer selected from the group consisting of breast, ovarian, endometrial and uterine cancer.

7. The method of claim 1, 2, 3, 4 or 5 wherein the CSG
comprises SEQ ID NO:2, 9 or 14 and the selected cancer is lung
30 cancer or a gynecologic cancer selected from the group consisting of ovarian, endometrial and uterine cancer.

- 41 -

8. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14 and the selected cancer is ovarian cancer.

9. An antibody against a CSG wherein said CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14.

5 10. A method of imaging a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10 12. A method of treating a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



DEX-0043

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C07K 16/8	A1	(11) International Publication Number: WO 00/12758 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19655 (22) International Filing Date: 1 September 1999 (01.09.99) (30) Priority Data: 60/098,880 2 September 1998 (02.09.98) US (71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment 218, 350 Elan Village Lane, San Jose, CA 95134 (US). (74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS		
(57) Abstract <p>The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.</p>		

7

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/098,880</u>	<u>September 2, 1998</u>
(Application Serial No.)	(Filing Date)
<u></u>	<u></u>
(Application Serial No.)	(Filing Date)
<u></u>	<u></u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u></u>	<u></u>	<u></u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u></u>	<u></u>	<u></u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u></u>	<u></u>	<u></u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



26259

PATENT TRADEMARK OFFICE

Send Correspondence to: **Jane Massey Licata or Kathleen A. Tyrrell**
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor Susana Salceda	Date 3/12/2001
Sole or first inventor's signature <i>Susana Salceda</i>	
Residence San Jose, California <i>CA</i>	
Citizenship Argentina	
Post Office Address 4118 Crescendo Avenue	
San Jose, California 95136	

Full name of second inventor, if any Yongming Sun	Date 4-17-01
Second inventor's signature <i>Yongming Sun</i>	
Residence San Jose, California <i>CA</i>	
Citizenship China	
Post Office Address 869 S. Winchester Boulevard, Apt. 260	
San Jose, California 95128	

3a Full name of third inventor, if any

Herve Recipon

Third inventor's signature

4-18-01

Date

Residence

San Francisco, California CA

Citizenship

France

Post Office Address

85 Fortuna AvenueSan Francisco, California 94115

4a Full name of fourth inventor, if any

Robert Cafferkey

Fourth inventor's signature

Date

3-12-01

Residence

San Jose, California CA

Citizenship

Ireland

Post Office Address

350 Elan Village Lane, Apt 218San Jose, California 95134

555 E WASHINGTON AVE, APT 1012W

SUNNYVALE, CA 94086

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

09/763978 #10

Rec'd PCT/PTO 30 APR 2002

1

SEQUENCE LISTING

<110> Salceda, Susana
Sun, Yongming
Recipon, Herve
Cafferkey, Robert

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND
TREATING VARIOUS CANCERS

<130> DEX-0172

<140> 09/763,978

<141> 2001-02-28

<150> PCT/US99/19655

<151> 1999-09-01

<150> 60/098,880

<151> 1998-09-02

<160> 15

<170> PatentIn version 3.1

<210> 1

<211> 2587

<212> DNA

<213> Homo sapien

<400> 1

ggaaggcagc gggcagctcc actcagccag taccagata cgctgggaac cttccccagc	60
catggcttcc ctggggcaga tcctcttctg gagcataatt agcatcatca ttattctggc	120
tggagcaatt gcactcatca ttggcttttg tatttcaggg agacactcca tcacagtcac	180
tactgtcgcc tcagctggga acattgggga ggatggaatc ctgagctgca cttttgaacc	240
tgacatcaaa ctttctgata tcgtgataca atggctgaag gaaggtgttt taggcttggt	300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaatgt tcagaggccg	360
gacagcagtg tttgctgac aagtgatagt tggcaatgcc tctttgcggc tgaaaaacgt	420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa	480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa	540
tgccagctca gagaccttgc ggtgtgaggg tccccgatgg tttccccagc ccacagtgg	600
ctgggcatcc caagttgacc agggagccaa cttctcggaa gtctccaata ccagctttga	660
gctgaactct gagaatgtga ccatgaagg tgtgtctgtg ctctacaatg ttacgatcaa	720
caacacatac tcctgtatga ttgaaaatga cattgccaaa gcaacagggg atatcaaagt	780
gacagaatcg gagatcaaaa ggcggagtca cctacagctg ctaaactcaa aggcttctct	840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat	900

2

gctaaaataa tgtgccttgg ccacaaaaaa gcatgcaaag tcattgttac aacagggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctgggag gaaatgaatt 1020
catatctaga agtctggagt gagcaaacaa gagcaagaaa caaaaagaag ccaaaagcag 1080
aaggctccaa tatgaacaag ataaatctat cttcaaagac atattagaag ttgggaaaat 1140
aattcatgtg aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200
tgcaccccca gatctcaggg acctccccct gctgtcacc tggggagtgag gaggacagga 1260
tagtgcattg tctttgtctc tgaattttta gttatatgtg ctgtaatgtt gctctgagga 1320
agccccctga aagtctatcc caacatatcc acatcttata ttccacaaat taagctgtag 1380
tatgtaccct aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440
tagtaatggg tcaaagtatt cactttttat gatgcttcca aaggctgctt ggcttctctt 1500
cccaactgac aaatgccaaa gttgagaaaa atgatcataa ttttagcata aacagagcag 1560
tcggcgacac cgattttata aataaactga gcaccttctt tttaaacaaa caaatgcggg 1620
tttatttctc agatgatgtt catccgtgaa tgggtccaggg aaggaccttt caccttgact 1680
atatggcatt atgtcatcac aagctctgag gcttctcctt tccatcctgc gtggacagct 1740
aagacctcag ttttcaatag catctagagc agtgggactc agctgggggtg atttcgcccc 1800
ccatctccgg gggaatgtct gaagacaatt ttggttacct caatgaggga gtggaggagg 1860
atacagtgtc actaccaact agtggataaa ggccagggat gctgctcaac ctctaccat 1920
gtacaggacg tctccccatt acaactaccc aatccgaagt gtcaactgtg tcaggactaa 1980
gaaaccctgg ttttgagtag aaaagggcct ggaaagaggg gagccaacaa atctgtctgc 2040
ttctcacatt agtcattggc aaataagcat tctgtctctt tggctgctgc ctacagacag 2100
agagccagaa ctctatcggg caccaggata acatctctca gtgaacagag ttgacaaggc 2160
ctatgggaaa tgctgatgg gattatcttc agcttggtga gcttctaagt ttctttccct 2220
tcattctacc ctgcaagcca agttctgtaa gagaaatgcc tgagttctag ctacaggtttt 2280
cttactctga atttagatct ccagaccctt cctggccaca attcaaatta aggcaacaaa 2340
catatacctt ccatgaagca cacacagact tttgaaagca aggacaatga ctgcttgaat 2400
tgaggccttg aggaatgaag ctttgaagga aaagaatact ttgtttccag ccccttccc 2460
acactcttca tgtgttaacc actgccttcc tggaccttgg agccacggtg actgtattac 2520
atgttggttat agaaaactga ttttagagtt ctgatcgttc aagagaatga ttaaataatac 2580
atttctt 2587

3

<210> 2
 <211> 2070
 <212> DNA
 <213> Homo sapien

<400> 2
 cacagagaga ggcagcagct tgctcagcgg acaaggatgc tgggcgtgag ggaccaaggc 60
 ctgccctgca ctcgggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120
 agccaggacc tgtgtgggga ggccctcctg ctgccttggg gtgacaatct cagctccagg 180
 ctacagggag accgggagga tcacagagcc agcatgttac aggatcctga cagtgatcaa 240
 cctctgaaca gcctcgatgt caaaccctg cgcaaaccgc gtatcccat ggagaccttc 300
 agaaaggtgg ggatcccat catcatagca ctactgagcc tggcgagtat catcattgtg 360
 gttgtcctca tcaaggtgat tctggataaa tactacttcc tctgcgggca gcctctccac 420
 ttcacccga ggaagcagct gtgtgacgga gagctggact gtcccttggg ggaggacgag 480
 gagcactgtg tcaagagctt cccgaaggc cctgcagtgg cagtcgcct ctccaaggac 540
 cgatccacac tgcaggtgct ggactcggcc acagggaact ggttctctgc ctgtttcgac 600
 aacttcacag aagctctcgc tgagacagcc tgtaggcaga tgggctacag cagcaaacc 660
 actttcagag ctgtggagat tggcccagac caggatctgg atgttgttga aatcacagaa 720
 aacagccagg agcttcgcat gcggaactca agtgggcct gtctctcagg ctccctggtc 780
 tccttgact gtcttgctg tgggaagagc ctgaagacc cccgtgtggt ggggtgggag 840
 gaggcctctg tggattcttg gccttggcag gtcagcatcc agtacgacaa acagcacgtc 900
 tgtggaggga gcatcctgga cccactggg gtccctcagg gcagccact gcttcaggaa 960
 acataccgat gtgttcaact ggaaggtgcg ggcaggctca gacaaactgg gcagcttccc 1020
 atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
 tgacatcgcc ctcatgaagc tgcagttccc actcactttc tcaggcacag tcaggcccat 1140
 ctgtctgccc ttctttgatg aggagctcac tccagccacc cactctgga tcattggatg 1200
 gggctttacg aagcagaatg gaggaagat gtctgacata ctgctgcagg cgtcagtcca 1260
 ggtcattgac agcacacggt gcaatgcaga cgatgcgtac cagggggaag tcaccgagaa 1320
 gatgatgtgt gcaggcatcc cggaaggggg tgtggacacc tgccagggtg acagtgggtg 1380
 gccctgatg taccaatctg accagtggca tgtggtgggc atcgtagct ggggctatgg 1440
 ctgccccggc ccgagcacc caggagtata caccaaggct tcagcctatc tcaactggat 1500
 ctacaatgtc tggaaggctg agctgtaatg ctgctgcccc ttgagcgtgc tgggagccgc 1560
 ttccttctg ccctgcccac ctggggatcc ccaaagtca gacacagagc aagagtcccc 1620

4

```

ttgggtacac ccctctgccc acagcctcag      catttcttgg agcagcaaag ggcctcaatt
1680

cctataagag accctcgcag cccagaggcg cccagaggaa gtcagcagcc ctagctcggc 1740
cacacttggt gctcccagca tcccaggagg agacacagcc cactgaacaa ggtctcaggg 1800
gtattgctaa gccaaagaag aactttccca cactactgaa tggaagcagg ctgtcttgta 1860
aaagcccaga tcactgtggg ctggagagga gaaggaaagg gtctgcgcca gcctgtccg 1920
tcttcacca tcccaagcc tactagagca agaaaccagt tgtaataata aatgcactgc 1980
cctactgttg gtatgactac cgttacctac tgttgcattg ttattacagc tatggccact 2040
attattaaag agctgtgtaa catctctggc      2070

<210> 3
<211> 1709
<212> DNA
<213> Homo sapien

<400> 3
agcagactca caccagaact acattccctg gccccctgcc tgtgtgcttc tggccaggcc 60
ttgggttgga agtctgaccc gagaaaagga tctgcagaaa atcagactat gggatcactt 120
tgtttgtgca ttgggaatga cattctttcc cccccagga aaacctttgg gactttcaga 180
gacattgttg ctagccaacc acatggtcag cctcaaagtt gagaggctca gtaaccctcc 240
tatccctaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
tgtgatectc tggaagtatg ctatgtttgt tatatcttgc atccaaagcc agagggaaacc 360
acaatgacta gtaaaacggg ggtctcaatg cccacttagc ctctgcctct gaatttgacc 420
atagtggcgt tcagctgata gagcgggaag aagaaatatg cattttttat gaaaaaataa 480
atatccaaga gaagatgaaa ctaaatggag aaattgaaat acatctactg gaagaaaaga 540
tccaattcct gaaaatgaag attgctgaga agcaaagaca aatttgtgtg acccagaaat 600
tactgccagc caagaggtcc ctggatgccg acctagctgt gctccaaatt cagttttcac 660
agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgat ggtgagaata 720
gagctcgctt ccttccaggg aaagatctga ccgaaaaaga aatgatccaa aaattagaca 780
agctggaact acaactggcc aagaaggagg agaagctgct ggagaaggat ttcattctatg 840
agcagggtctc caggctcaca gacaggctct gcagcaaac tcagggctgc aagcaggaca 900
cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
aaatgatggc tcttgttgct gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
aggaagtcat ggagaaagaa gacttcatct tcaattgcaa ttccaggata gaaaaaggtc 1080

```

5

tgccactcaa taaggaaatt gagaaagaat ggttgaaagt ccttcgagat gaagaaatgc
1140

acgccttggc catcgctgaa aagtctcagg agttcttggga agcagataat cgccagctgc 1200

ccaatggtgt ttacacaact gcagagcagc gtccgaatgc ctacatccca gaagcagatg 1260

ccactcttcc ttgccaataa ccttatggtg ctttggtctcc ttttaaaccg agtgaacctg 1320

gagccaatat gaggcacata aggaaacctg ttataaagcc agttgaaatc tgaatatgtg 1380

aacaaatcca ggctcttcaa ggaaaagact tcaaccaggc ttccttgtac ccacaggtga 1440

aaaatgtgag cataatactt ctaatattat tgataagtaa ggtaaccaca attagtcagc 1500

aacagagtac aacagggttt ctatttaccg accaactact atacctttca tgacgttgaa 1560

tgggacatag aactgtccta catttatgtc aaagtatata tttgaatcgc ttatattttc 1620

tttttcactc ttatatttga gtacattcca gaaatttgta gtaggcaagg tgctataaaa 1680

atgcactaaa aataaatctg ttctcaatg 1709

<210> 4
<211> 257
<212> DNA
<213> Homo sapien

<400> 4
ttaatgggta agtatttttt atatgcttta gctatagcta aagaaaactg atacttaaca 60

aagttgaata gtattattca ctgggtgctc taaaatattg tttttcagtg taaaatatgc 120

atatcttcta tatttaatat gaaagtcttg aaatgtatca gacagaaggg gatttcagtt 180

tgcaaataat gagcaatgta gcaattttta cacatttcat aaatatatat tttgtcattg 240

gtggagagca ccatttg 257

<210> 5
<211> 359
<212> DNA
<213> Homo sapien

<400> 5
gcctgagagc acttagcggt catgagtgtc ccaccatgg cctggatgat gcttctcctc 60

ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggg gacccaagag 120

ccatcgttat cagtgtcccc tggagggaca gtcacactca cttgtggctt ggctcttgac 180

tcagtctcta ctaatttctt cccacctgg taccagcaga cccaggcca ggctccacgc 240

acgtcatct acagcacaag cactcgctct tctgggggtc ctgatcggtt ctctggctcc 300

atccttggga acaaagctgc cctcaccatt acggggggcc aggcagatga tgaatctga 359

6

<210> 6
 <211> 1372
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n = a, c, g or t

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n = a, c, g or t

<400> 6
 ccttanagnc ttggttgcca aacagaatgc ccatatccgt cttacttggtg aggaagcttg 60
 ccttggggcgc cctctgctgg ccctcctgaa gctaacaggg gcgagtgtc ggtgggtttac 120
 aaattgcctc catgcagact atgaaactgt tcagcctgct atagttagat ctctggcact 180
 ggcccaggag gtcttgacaga ttgacagatc aaggagaacc caggagtttc aaagaagcgg 240
 ctagtaaagg tctctgagat ccttgacta gctacatcct cagggttagga ggaagatggc 300
 ttccagaagc atgcggctgc tcctattgct gagctgcctg gccaaaacag gagtccctggg 360
 tgatatcatc atgagacca gctgtgctcc tgggatgggt ttaccacaag tccaattgct 420
 atgggttactt caggaagctg aggaactggt ctgatgccga gctcgagtgt cagtcttacg 480
 gaaacggagc ccacctggca tctatcctga gtttaaagga agccagcacc atagcagagt 540
 acataagtgg ctatcagaga agccagccga tatggattgg cctgcacgac ccacagaaga 600
 ggcagcagtg gcagtggatt gatggggcca tgtatctgta cagatcctgg tctggcaagt 660
 ccatgggttg gaacaagcac tgtgctgaga tgagctcaa taacaacttt ttaacttgga 720
 gcagcaacga atgcaacaag cgccaacact tcctgtgcaa gtaccgacca tagagcaaga 780
 atcaagattc tgctaactcc tgcacagccc cgtcctcttc ctttctgcta gcctggctaa 840
 atctgctcat tatttcagag gggaaaccta gaaactaag agtgataagg gccctactac 900
 actggctttt ttaggcttag agacagaaac tttagcattg gccagtagt ggcttctagc 960
 tctaaatgtt tgccccgcca tccctttcca cagtatcctt cttccctcct ccctgtctc 1020
 tggctgtctc gagcagtcta gaagagtga tctccagcct atgaaacagc tgggtctttg 1080
 gccataagaa gtaaagattt gaagacagaa ggaagaaact caggagtaag cttctagccc 1140
 ccttcagctt ctacaccctt ctgccctctc tccattgcct gcacccacc ccagccactc 1200
 aactcctgct tgtttttcct ttggccatgg gaaggtttac cagtagaatc cttgctaggt 1260


```
<400>      8
attctagaac atatgtataa gctaaaaaaca gtattttact cagatcagta gttatcgtgt      60
ctatcagcta taaaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat      120
tatagaaccg ttttgtgtag cattggaata ttgtccattt tgtaagtcac tgtgaatggt      180
cttaattatc agcttgaagg tattttttgta ttaaaagttg acattgaaga acctaaagtg      240
```

```

atgatgggat ttggggccag tagtgaaagt atgtttcctc taaaatattt ccctaaacag 300
tggtatacat gggtatttta ttatgagatt tgtatatgtt ctgtgtttct ctgtgaacaa 360
tgtttcagtc tctctgtcac catatgtaag gggaagtcca caaatatagn actacattgc 420
acaaaactaa aattgttaat tacaagaaaa tataggtgct taccttttga aggtttatta 480
atacatatgg ttgtcacaat acgtatatat gataaatggg gtacatatat agatgtttat 540
gggtgtataaa tttttctata cccaattaga attatcttcc tgattcttta ttcaataaca 600
tgctaattcc tcttctatgt tctatagtga cagaatgcta acttttctta taccctggca 660
gaggacagag gagtctggtc taggatgggg aactgaattt ttgaacgaaa aggaaagaga 720
aaggatgnnn nnnnnnnnnn nnnnnnnnnn nnnnnntaat gtttcttagt cattttgatt 780
ggccatttga acagtctaca agtttaacgt tatttccagt gaagtaggat ggctgaccta 840
gcaatacatg tttcttcaaa agggtaaaca tgcttttagt acctaaagct aaattttgta 900
catttgacat caggggtggt ataagtactg cacttaatac aaagctattt ctcaatngtg 960
ttatTTTTGA gacaaatttt tcttcaccat taacttcttg ttggtagctt tttgttttgt 1020
aaaaattgag agatggcaat gcttatctca accagattat ccatctgcag aattaaggta 1080
tgcaactggg aaataaaaaga caaatgctcc agtttgtctt tctcaacctt tgagttctta 1140
acctttgagt taaaacctag tctaaatagt gggaatgtct tgggtttacag taaggttttc 1200
ttgggaagga tcttggtttt gtgatctatt tgtgaattaa ggagtagatg ttaaccatta 1260
ttttatagat aagtg 1275

```

```

<210> 9
<211> 2479
<212> DNA
<213> Homo sapien

```

```

<400> 9
gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gacctacta tgaaaaccat ggataccaac 120
cggaaaaccc ctatcccgca cagccactg tggccccac tgtctacgag gtgcatccgg 180
ctcagtacta cccgtcccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
accccgtcgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgacctgg ggaccttct cgtgggagct gcgctggccg 360
ctggcctact ctggaagttc atgggcagca agtgcctcaa ctctgggata gagtgcgact 420
cctcaggtac ctgcatcaac cctctaaact ggtgtgatgg cgtgtcacac tgccccggcg 480

```

gggaggacga gaatcggtgt gttegcctct acggaccaa cttcatcctt cagatgtact
 540
 catctcagag gaagtccctg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600
 ggggggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
 atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
 ataaaaaact gtaccacagt gatgcctgtt cttcaaaagc agtgggttct ttacgctgtt 780
 tagcctgcgg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840
 cgctcccggg ggctggccc tggcaggtea gctgcacgt ccagaacgtc cacgtgtgcg 900
 gaggtcccat catcaccccc gagtggatcg tgacagccgc cactgcgtg gaaaaacctc 960
 ttaacaatcc atggcatttg acggcatttg cggggatttt gagacaatct ttcattgtct 1020
 atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080
 agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140
 aaccagtgtg tctgccaac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200
 ccgggtgggg ggccaccgag gagaaagga agacctcaga agtgcagaac gctgccaaag 1260
 tgcttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320
 cagccatgat ctgtgccggc ttctgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380
 gagggcctct ggtcacttcg aacaacaata tctgggtggc gataggggat acaagctggg 1440
 gttctggctg tgccaaagct tacagaccag gagtgtacgg gaatgtgatg gtattcacgg 1500
 actggattta tcgacaaatg aaggcaaacg gctaataccac atggctcttcg tcttgacgt 1560
 cgttttacaa gaaaacaatg gggtgggtt tgcttccccg tgcatgattt actcttagag 1620
 atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680
 tgccatactg tgcaggctgc agtggctccc ctgccagcc tgctctccct aacccttgt 1740
 ccgcaagggg tgatggccgg ctgggtgtgg gactggcgg tcaattgtgg aaggaagagg 1800
 gttggaggct gccccattg agatcttctt gctgagtcct ttccaggggc caattttgga 1860
 tgagcatgga gctgtcactt ctacagctgt ggatgacttg agatgaaaaa ggagagacat 1920
 ggaaagggag acagccaggt ggcacctgca gcggctgcc tctggggcca cttggtagtg 1980
 tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040
 gatgggtggc agaaataaag ggaccagccc ttcattgggtg tgacgtggg agtcacttgt 2100
 aaggggaaca gaaacatttt tgttcttatg gggtgagaat atagacagtg cccttgggtg 2160
 gaggggaagca attgaaaagg aacttgccct gagcactcct ggtgcaggtc tccacctgca 2220
 cattgggtgg ggctcctggg agggagactc agccttcctc ctcatcctcc ctgacctgc 2280

10

tcctagcacc ctggagagtg aatgccccctt ggtccctggc agggcgccaa gtttggcacc 2340
atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400
atgctcagtt taaggtagac tggtttccatg ttatgtttct acacattgat ggtgggtgacc 2460
ctgagttcaa agccatctt 2479

<210> 10
<211> 576
<212> DNA
<213> Homo sapien

<400> 10
ttcaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tgtgttaaga 60
gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcaggga cctccccctg 120
cctgtcacct ggggagtgag aggacaggat agtgcattgt ctttgtctct gaatttttag 180
ttatatgtgc tgtaatgttg ctctgaggaa gccctggaa agtctatccc aacatatcca 240
catcttatat tccacaaatt aagctgtagt atgtacccta agacgctgct aattgactgc 300
cacttcgcaa ctcagggggc gctgcatttt agtaatgggt caaatgattc actttttatg 360
atgcttccaa aggtgccttg gcttctcttc ccaactgaca aatgccaaag ttgagaaaaa 420
tgatcataat tttagcataa acagagcagt cggcgacacc gattttataa ataaactgag 480
caccttcttt ttaaacaaac aaatgcgggt ttatttctca gatgatgttc atccgtgaat 540
ggtccaggga aggacctttc accttgacta tatggc 576

<210> 11
<211> 890
<212> DNA
<213> Homo sapien

<400> 11
caagctctga ggcttctcct ttccatcctg cgtggacagc taagacctca gttttcaata 60
gcatctagag cagtgggact cagctggggt gatttcgccc cccatctccg ggggaatgtc 120
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtgc tactaccaac 180
tagtggataa aggccaggga tgctgctcaa cctcctacca tgtacaggga cgtctcccca 240
ttacaactac ccaatccgaa gtgtcaactg tgtcaggact aagaaacctt ggttttgagt 300
agaaaagggc ctggaaagag gggagccaac aaatctgtct gcttctctac attagtcatt 360
ggcaaataag cattctgtct ctttggctgc tgcctcagca cagagagcca gaactctatc 420
gggcaccagg ataacatctc tcagtgaaca gagttgacaa ggcctatggg aaatgcctga 480
tgggattatc ttcagcttgt tgagcttcta agtttcttct ccttcattct accctgcaag 540

11

```

ccaagttctg taagagaaat gcctgagttc tagctcaggt tttcttactc tgaatttaga      600
tctccagacc cttcctggcc acaattcaaa ttaaggcaac aaacatatac cttccatgaa      660
gcacacacag acttttgaaa gcaaggacaa tgactgcttg aattgaggcc ttgaggaatg      720
aagctttgaa ggaaaagaat actttgtttc cagccccctt cccacactct tcatgtgtta      780
accactgcct tcttggacct tggagccacg gtgactgtat tacatgttgt tatagaaaac      840
tgatttttaga gttctgatcg ttcaagagaa tgattaaata tacatttctt      890

```

```

<210> 12
<211> 406
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (30)..(30)
<223> n= a, c, g, or t

```

```

<220>
<221> misc_feature
<222> (248)..(248)
<223> n= a, c, g, or t

```

```

<220>
<221> misc_feature
<222> (383)..(383)
<223> n= a, c, g, or t

```

```

<400> 12
gtgaatgtgg actataatgc cagctcagan accttgcggt gtgaggctcc ccgatggttc      60
ccccagccca cagtgggtctg ggcaccccaa gttgaccagg gagccaactt ctcggaagtc      120
tccaatacca gctttgagct gaactctgag aatgtgacca tgaaggttgt gtctgtgctc      180
tacaatgtta cgatcaacaa cacatactcc tgtatgattg aaaatgacat tgccaaagca      240
acaggggnta tcaaagtgac agaatcgag atcaaaaggc ggagtcacct acagctgcta      300
aactcaaagg cttctctgtg tgtctcttct ttctttgcca tcagctgggc acttctgcct      360
ctcagccctt acctgatgct aanataatgt gccttggcca caaaaaa      406

```

```

<210> 13
<211> 462
<212> DNA
<213> Homo sapien

```

```

<400> 13
ggaaggcagc ggcagctcca ctcagccagt acccagatac gctgggaacc ttccccagcc      60

```

12

```

atggcttccc tggggcagat cctcttctgg agcataatta gcatcatcat tattctggct 120
ggagcaattg cactcatcat tggctttggg atttcagggg gacactccat cacagtcact 180
actgtcgctt cagctgggaa cattggggag gatggaatcc tgagctgcac ttttgaacct 240
gacatcaaac tttctgatat cgtgatacaa tggctgaagg aagggtgtttt aggcttggtc 300
catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggccgg 360
acagcagtgt ttgctgatca agtgatagtt ggcaatgcct ctttgcggct gaaaaacgtg 420
caactcacag atgctggcac ctacaaatgt tatatcatca ct 462

```

```

<210> 14
<211> 272
<212> DNA
<213> Homo sapien

```

```

<400> 14
gcagcttgct cagcggacaa ggatgctggg cgtgagggac caaggcctgc cctgcactcg 60
ggcctcctcc agccagtgtt gaccagggac ttctgacctg ctggccagcc aggacctgtg 120
tggggaggcc ctcttctgct cttgggggtga caatctcagc tccaggctac agggagaccg 180
ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gcctctgcaa 240
ggtgattctg gataaatact acttcctctg cg 272

```

```

<210> 15
<211> 492
<212> PRT
<213> Homo sapien

```

<400> 15

```

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
1          5          10          15

```

```

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
20          25          30

```

```

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
35          40          45

```

```

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
50          55          60

```

```

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys
65          70          75          80

```

13

Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
85 90 95

Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
100 105 110

Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
115 120 125

Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
130 135 140

Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met
145 150 155 160

Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
165 170 175

Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
180 185 190

Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
195 200 205

Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys
210 215 220

Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg
225 230 235 240

Cys Leu Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile
245 250 255

Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser
260 265 270

Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro
275 280 285

Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn
290 295 300

Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met
305 310 315 320

Phe Tyr Gly Ala Gly Tyr Gln Val Gln Lys Val Ile Ser His Pro Asn
 325 330 335

Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln
 340 345 350

Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn
 355 360 365

Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp
 370 375 380

Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala
 385 390 395 400

Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr
 405 410 415

Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly
 420 425 430

Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser
 435 440 445

Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly
 450 455 460

Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe
 465 470 475 480

Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly
 485 490

SEQUENCE LISTING

<110> Salceda, Susana
 Sun, Yongming
 Recipon, Herve
 Cafferkey, Robert
 DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
 IMAGING AND TREATING VARIOUS CANCERS

<130> DEX-0043

<140>

<141>

<150> 60/098,880

<151> 1998-09-02

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 2587

<212> DNA

<213> Homo sapiens

<400> 1

```

ggaaggcagc gggcagctcc actcagccag taccagata cgctgggaac cttccccagc 60
catggccttc ctggggcaga tcctcttctg gagcataatt agcatcatca ttattctggc 120
tgagcaatt gcaactcatca ttggctttgg tatttcaggg agacactcca tcacagtcac 180
tactgtcgcc tcagctggga acattgggga ggatggaatc ctgagctgca cttttgaacc 240
tgacatcaaa ctttctgata tcgtgataca atggctgaag gaaggtgttt taggcttggg 300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaatgt tcagaggccg 360
gacagcagtg tttgctgatc aagtgatagt tggcaatgcc tctttgcggc tgaaaaacgt 420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa 480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa 540
tgccagctca gagaccttgc ggtgtgaggc tccccgatgg ttccccagc ccacagtggg 600
ctgggcatcc caagttgacc agggagccaa cttctcgaa gtctccaata ccagctttga 660
gctgaactct gagaatgtga ccatgaaggt tgtgtctgtg ctctacaatg ttacgatcaa 720
caacacatac tcctgtatga ttgaaaatga cattgccaaa gcaagggggg atatcaaagt 780
gacagaatcg gagatcaaaa ggcggagtca cctacagctg ctaaactcaa aggccttctc 840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat 900
gctaaaataa tgtgccttgg ccacaaaaaa gcatgcaaag tcattgttac aacagggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctgggag gaaatgaatt 1020
catatctaga agtctggagt gagcaaaca gagcaagaaa caaaaagaag ccaaaagcag 1080
aaggctccaa tatgaacaag ataaatctat cttcaaagac atattagaag ttgggaaaat 1140

```

WO 00/12758

PCT/US99/19655

```

aattcatgtg aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200
tgcattcccca gatctcaggg acctccccct gcctgtcacc tggggagtgga gaggacagga 1260
tagtgcatgt tctttgtctc tgaattttta gttatatgtg ctgtaatgtr gctctgagga 1320
agcccttgga aagtctatcc caacatatcc acatcttata ttccacaaat taagctgtag 1380
tatgtacctt aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440
tagtaatggg tcaaattgatt cactttttat gatgcttcca aaggtgcctt ggcttctctt 1500
cccaactgac aaatgccaaa gttgagaaaa atgatcataa ttttagcata aacagagcag 1560
tcggcgacac cgattttata aataaaactga gcaccttctt tttaaacaaa caaatgcggg 1620
tttattttctc agatgatggt catccgtgaa tgggtccaggg aaggaccttt cacttgact 1680
atatggcatt atgtcatcac aagctctgag gcttctcctt tccatcctgc gtggacagct 1740
aagacctcag ttttcaatag catctagagc agtgggactc agctggggtg atttcgcccc 1800
ccatctccgg gggaatgtct gaagacaatt ttggttacct caatgaggga gtggaggagg 1860
atacagtgtc actaccaact agtggataaa ggccagggat gctgctcaac ctctaccat 1920
gtacaggacg tctccccatt acaactaccc aatccgaagt gtcaactgtg tcaggactaa 1980
gaaaccttg ttttgagtag aaaagggcct ggaaagaggg gagccaacaa atctgtctgc 2040
ttctcacatt agtcattggc aaataagcat tctgtctctt tggctgctgc ctacgacag 2100
agagccagaa ctctatcggg caccaggata acatctctca gtgaacagag ttgacaaggc 2160
ctatgggaaa tgctgatgg gattatcttc agcttgttga gcttctaagt ttctttccct 2220
tcattctacc ctgcaagcca agttctgtaa gagaaatgcc tgagttctag ctacaggttt 2280
cttactctga atttagatct ccagacctt cctggccaca attcaaatta aggcaacaaa 2340
catatacctt ccatgaagca cacacagact tttgaaagca aggacaatga ctgcttgaat 2400
tgaggccttg aggaatgaag ctttgaagga aaagaatact ttgtttccag ccccttccc 2460
acactcttca tgtgttaacc actgccttcc tggaccttgg agccacggtg actgtattac 2520
atgttgttat agaaaactga ttttagagtt ctgatcgttc aagagaatga ttaaataatac 2580
atttctt

```

<210> 2

<211> 2070

<212> DNA

<213> Homo sapiens

<400> 2

```

cacagagaga ggcagcagct tgctcagcgg acaaggatgc tgggcgtgag ggaccaaggc 60
ctgccctgca ctggggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120
agccaggacc tgtgtgggga ggccctcctg ctgccttggg gtgacaatct cagctccagg 180
ctacagggag accgggagga tcacagagcc agcatgttac aggatcctga cagtgatcaa 240
cctctgaaca gcctcgatgt caaacccctg cgcaaaccct gtatcccat ggagaccttc 300
agaaagggtg ggatcccat catcatagca ctactgagcc tggcgagtat catcattgtg 360
gttgctctca tcaagggtgat tctggataaa tactacttcc tctgcgggca gcctctccac 420
ttcatccga ggaagcagct gtgtgacgga gagctggact gtcccttggg ggaggacgag 480
gagcactgtg tcaagagctt ccccgagggg cctgcagtgg cagtccgcct ctccaaggac 540
cgatccacac tgcaggtgct ggactcggcc acagggaact ggttctctgc ctgtttcgac 600
aacttcacag aagctctcgc tgagacagcc tgtaggcaga tgggctacag cagcaaacc 660
actttcagag ctgtggagat tggcccagac caggatctgg atgttggtga aatcacagaa 720
aacagccagg agcttcgcat gcggaactca agtgggcctt gtctctcagg ctccctggtc 780
tccctgcact gtcttgctg tgggaagagc ctgaagaccc cccgtgtggt ggggtgggag 840
gaggcctctg tggattcttg gccttggcag gtcagcatcc agtacgacaa acagcacgtc 900
tgtggaggga gcattcctga ccccaactgg gtccctcagc gcagccact gcttcaggaa 960

```

WO 00/12758

PCT/US99/19655

```

acataccgat gtgttcaact ggaaggtgcg ggcaggetca gacaaactgg gcagcttccc 1020
atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
tgacatcgcc ctcatgaagc tgcagttccc actcactttc tcaggcacag tcaggcccat 1140
ctgtctgccc ttctttgatg aggagctcac tccagccacc ccactctgga tcattgggat 1200
gggctttacg aagcagaatg gaggaagat gtctgacata ctgctgcagg cgtcagtcca 1260
ggtcattgac agcacacggg gcaatgcaga cgatgcgtac cagggggaag tcaccgagaa 1320
gatgatgtgt gcaggcatcc cggaaggggg tgtggacacc tgccagggtg acagtgggtg 1380
gccctgatg taccaatctg accagtggca tgtggtggg atcgttagct ggggctatgg 1440
ctgcgggggc ccgagcacc caggagtata caccaaggtc tcagcctatc tcaactggat 1500
ctacaatgtc tggaaggctg agctgtaatg ctgctgcccc tttgcagtgc tgggagccgc 1560
ttcttctctg ccctgcccac ctggggatcc cccaaagtca gacacagagc aagagtcccc 1620
ttgggtacac ccctctgccc acagcctcag catttcttgg agcagcaaag ggcctcaatt 1680
cctataagag accctcgtag cccagaggcg cccagaggaa gtcagcagcc ctagctcggc 1740
cacacttggg gctcccagca tcccagggag agacacagcc cactgaacaa ggtctcaggg 1800
gtattgctaa gccaaagaag aactttccca cactactgaa tggaagcagg ctgtcttgta 1860
aaagcccaga tcaactgtgg ctggagagga gaaggaaagg gtctgcgcca gccctgtccg 1920
tcttcaccca tcccaagcc tactagagca agaaaccagt tgtaataata aatgcactgc 1980
cctactgttg gtatgactac cgttacctac tgttgcatg ttattacagc tatggccact 2040
attattaaag agctgtgtaa catctctggc 2070

```

<210> 3

<211> 1709

<212> DNA

<213> Homo sapiens

<400> 3

```

agcagactca caccagaact acattccctg gcccctgccc tgtgtgcttc tggccaggcc 60
ttggttggca agtctgaccc gagaaaagga tctgcagaaa atcagactat gggatcactt 120
tgtttgtgca ttgggaatga cattctttcc cccccagga aaacctttgg gactttcaga 180
gacattgttg ctagccaacc acatggtcag cctcaaagtt gagaggctca gtaaccctcc 240
tatccctaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
tgtgatcctc tggaagtatg ctatgttgtg tatatcttgc atccaaagcc agaggggaacc 360
acaatgacta gtaaaacggg ggtctcaatg ccacttagc ctctgctct gaatttgacc 420
atagtggcgt tcagctgata gagcgggaag aagaaatatg cattttttat gaaaaataa 480
atatccaaga gaagatgaaa ctaaatggag aaattgaaat acatctactg gaagaaaaga 540
tccaattcct gaaaatgaag attgctgaga agcaaagaca aatttgtgtg acccagaaat 600
tactgccagc caagagggtc ctggatgccg acctagctgt gctccaaatt cagttttcac 660
agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgat ggtgagaata 720
gagctcgctt ccttccaggg aaagatctga ccgaaaaaga aatgatccaa aaattagaca 780
agctggaact acaactggcc aagaaggagg agaagctgct ggagaaggat ttcatctatg 840
agcagggtct caggctcaca gacaggctct gcagcaaaac tcagggtctg aagcaggaca 900
cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
aaatgatggc tcttgttgct gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
aggaagttag ggagaaagaa gacttcatct tcaattgcaa ttccaggata gaaaaaggtc 1080
tgccactcaa taaggaaatt gagaaagaat ggttgaaagt ccttcgagat gaagaaatgc 1140
acgccttggc catcgctgaa aagtctcagg agttcttgga agcagataat cgccagctgc 1200
ccaatggtgt ttacacaact gcagagcagc gtccgaatgc ctacatccca gaagcagatg 1260
ccactcttcc tttgccaaaa ccttatgggtg ctttggctcc ttttaaacc agtgaacctg 1320

```

WO 00/12758

PCT/US99/19655

<210> 4
<211> 257
<212> DNA
<213> Homo sapiens

<400> 4
ttaatgggta agtatttttt atatgcttta gctatagcta aagaaaactg atacttaaca 60
aagttgaata gtattattca ctgggtgctcc taaaatatTTg tttttcagtg taaaatatgc 120
atatcttcta tatttaatat gaaagtctttg aaatgtatca gacagaaggg gattttcagtt 180
tgcaaataat gagcaatgta gcaattttta cacatttcat aaatatatat tttgtcattg 240
gtggagagca ccatttg 257

<210> 5
<211> 359
<212> DNA
<213> Homo sapiens

<400> 5
gcctgagagc acttagcggt catgagtgtc cccaccatgg cctggatgat gcttctcctc 60
ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggt gaccaagag 120
ccatcggttat cagtgtcccc tggagggaca gtcacactca ctgttggtt ggccctctgac 180
tcagtctcta ctaatttctt cccacctgg taccagcaga cccaggcca ggctccacgc 240
acgtcctatc acagcacaag cactcgtctc tctgggggtc ctgategttt ctctgggtcc 300
atccttgagg acaaagctgc cctcaccatt acggggggccc aggcagatga tgaatctga 359

<210> 6
<211> 1372
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (6)

<220>
<221> unsure
<222> (9)

<400> 6
ccttanagnc ttgggtgcc aacagaatgc ccatatccgt cttacttgtg aggaagcttg 60

WO 00/12758

PCT/US99/19655

<220>
<221> unsure
<222> (728)..(756)

<220>
<221> unsure
<222> (957)

<400> 8
attctagaac atatgtataa gctaaaaaca gtattttact cagatcagta gttatcgtgt 60
ctatcagcta taaaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat 120
tatagaaccg ttttgcgtag cattggaata ttgtccattt tgtaagtcac tgtgaatggt 180
cttaattatc agcttgaagg tatttttcta ttaaaagtgt acattgaaga acctaaagtg 240
atgatgggat ttggggccag tagtgaaagt atgtttcctc taaaatatat ccctaaacag 300
tggtatacat gggtatttta ttatgagatt tgtatatgtt ctgtgtttct ctgtgaacaa 360
tgtttcagtc tctctgtcac catatgtaag gggaagtcca caaatatagn actacattgc 420
acaaaactaa aattgttaat tacaagaaaa tatagggtgt taccttttga aggtttatta 480
atacatatgg ttgtcacaat acgtatatat gataaatggg gtacatatat agatgtttat 540
gggtgtataaa tttttctata cccaattaga attatcttcc tgattcttta ttcaataaca 600
tgctaattcc tcttctatgt tctatagtga cagaatgcta acttttctta taccctggca 660
gaggacagag gagtctgggc taggatgggg aactgaattt ttgaacgaaa aggaaagaga 720
aaggatgnnn nnnnnnnnnn nnnnnnnnnn nnnnnntaat gtttcttagt cattttgatt 780
ggccatttga acagtctaca agtttaacgt tatttccagt gaagtaggat ggctgacct 840
gcaatacatg tttcttcaaa agggtaaaaca tgcttttagt acctaaagct aaattttgta 900
catttgacat caggggtggt ataagtactg cacttaatac aaagctattt ctcaatngtg 960
ttatttttga gacaaatttt tcttcaccat taacttcttg ttggtagctt tttgttttgt 1020
aaaaattgag agatggcaat gcttatctca accagattat ccactctgcag aattaaggta 1080
tgcaactggt aaataaaaaga caaatgctcc agtttgtctt tctcaacctt tgagttctta 1140
acctttgagt taaaacctag tctaaatagt gggaatgtct tggtttacag taaggttttc 1200
ttgggaagga tcttggtttt gtgatctatt tgtgaattaa ggagtagatg ttaaccatta 1260
ttttatagat aagtg 1275

<210> 9
<211> 2479
<212> DNA
<213> Homo sapiens

<400> 9
gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaacccat ggataccaac 120
cggaaaaacc ctatcccga cagcccactg ttgtcccccac tgtctacgag gtgcatccgg 180
ctcagtacta cccgtccccc gtgcccaggt acgccccgag ggtcctgacg caggcttcca 240
accccgctgt ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgacctgg ggaccttctt cgtgggagct gcgctggccg 360
ctggcctact ctggaagtgc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
cctcaggtag ctgcatcaac cctctaaact ggtgtgatgg cgtgtcacac tgccccggcg 480
gggaggacga gaatcggtgt gtgcgcctct acggacaaa cttcatcctt cagatgtact 540
catctcagag gaagtcctgg caccctgtgt gccaaagacga ctggaacgag aactacgggc 600

WO 00/12758

PCT/US99/19655

```

gggcggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660
atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
ataaaaaact gtaccacagt gatgcctggt cttcaaaagc agtggtttct ttacgctggt 780
tagcctgcgg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840
cgctcccggg ggcttggccc tggcaggtca gcctgcacgt ccagaacgtc cacgtgtgcg 900
gaggctccat catcaccccc gagtggatcg tgacagccgc ccactgcgtg gaaaaacctc 960
ttaacaatcc atggcatttg acggcatttg cggggatttt gagacaatct ttcattgtct 1020
atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080
agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140
aaccagtgtg tctgcccac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200
ccgggtgggg ggccaccgag gagaaaggga agacctcaga agtgcgaac gctgccaagg 1260
tgctttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320
cagccatgat ctgtgccggc ttcttgcagg ggaacgtcga ttcttgccag ggtgacagtg 1380
gagggcctct ggtcacttcg aacaacaata tctggtggct gataggggat acaagctggg 1440
gttctggctg tgccaaagct tacagaccag gagtgtacgg gaatgtgatg gtattcacgg 1500
actggattta tcgacaaatg aaggcaaacg gctaattccac atggtcttcg tccttgacgt 1560
cgttttacaa gaaaacaatg gggtctggtt tgcttccccg tgcatgattt actcttagag 1620
atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680
tgccatactg tgcaggctgc agtggctccc ctgccagcc tgctctccct aacccttgt 1740
ccgcaagggg tgatggccgg ctggttgtgg gcactggcgg tcaattgtgg aaggaagagg 1800
gttgagggt gccccattg agatcttctt gctgagtcct ttccaggggc caattttgga 1860
tgagcatgga gctgtcactt ctacagctgct ggatgacttg agatgaaaaa ggagagacat 1920
ggaaagggag acagccaggt ggcacctgca gcggctgcc tctggggcca cttggtagtg 1980
tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040
gatggtggcc agaaataaag ggaccagccc ttcattgggt gtgacgtggt agtcacttgt 2100
aaggggaaca gaaacatttt tgttcttatg gggtgagaat atagacagtg ccttggtgct 2160
gaggggaagca attgaaaagg aacttgcctt gagcactcct ggtgcaggtc tccacctgca 2220
cattgggtgg ggctcctggg agggagactc agccttcttc ctcatcctcc ctgacctgct 2280
tcctagcacc ctggagagtg aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340
atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400
atgtcagtt taaggtacac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460
ctgagttcaa agccatctt
2479

```

<210> 10

<211> 576

<212> DNA

<213> Homo sapiens

<400> 10

```

ttcaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tgtgttaaga 60
gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcagga cctccccctg 120
cctgtcacct ggggagtgag aggacaggat agtgcattgt ctttgtctct gaatttttag 180
ttatatgtgc tgtaatgttg ctctgaggaa gcccttgaa agtctatccc aacatatcca 240
catcttatat tccacaaatt aagctgtagt atgtacccta agacgctgct aattgactgc 300
cacttcgcaa ctccaggggcg gctgcatttt agtaatgggt caaatgattc actttttatg 360
atgcttccaa aggtgccttg gcttctcttc ccaactgaca aatgccaaag ttgagaaaaa 420
tgatcataat ttagcataa acagagcagt cggcgacacc gattttataa ataaactgag 480
caccttcttt ttaaacaac aaatgcgggt ttatttctca gatgatgttc atccgtgaat 540

```


ctcagccctt acctgatgct aanataatgt gccttggcca caaaaa

406

<210> 13

<211> 462

<212> DNA

<213> Homo sapiens

<400> 13

ggaaggcagc ggcagctcca ctcagccagt acccagatac gctgggaacc ttccccagcc 60
 atggttccc tggggcagat cctcttctgg agcataatta gcatcatcat tatcttggt 120
 ggagcaattg cactcatcat tggcttttgt atttcaggga gacactccat cacagtcact 180
 actgtcgcct cagctgggaa cattggggag gatggaatcc tgagctgcac ttttgaacct 240
 gacatcaaac tttctgatat cgtgatacaa tggtgaagg aaggtgtttt aggcttggtc 300
 catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggccgg 360
 acagcagtgt ttgctgatca agtgatagtt ggcaatgcct ctttgcggt gaaaaacgtg 420
 caactcacag atgctggcac ctacaaatgt tatatcatca ct 462

<210> 14

<211> 272

<212> DNA

<213> Homo sapiens

<400> 14

gcagcttgct cagcggacaa ggatgctggg cgtgaggac caaggcctgc cctgcactcg 60
 ggctcctcc agccagtgt gaccaggac ttctgacctg ctggccagcc aggacctgtg 120
 tggggaggcc ctctgctgc cttgggtga caatctcagc tccaggctac agggagaccg 180
 ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gctctgcaa 240
 ggtgattctg gataaatact acttcctctg cg 272

<210> 15

<211> 492

<212> PRT

<213> Homo sapiens

<400> 15

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
 1 5 10 15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
 20 25 30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
 35 40 45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
 50 55 60

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys

65 70 75 80
 Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val
 85 90 95
 Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys
 100 105 110
 Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn
 115 120 125
 Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp
 130 135 140
 Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met
 145 150 155 160
 Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp
 165 170 175
 Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn
 180 185 190
 Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser
 195 200 205
 Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys
 210 215 220
 Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg
 225 230 235 240
 Cys Leu Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile
 245 250 255
 Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser
 260 265 270
 Leu His Val Gln Asn Val His Val Cys Gly Gly Ser Ile Ile Thr Pro
 275 280 285
 Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn
 290 295 300
 Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met
 305 310 315 320
 Phe Tyr Gly Ala Gly Tyr Gln Val Gln Lys Val Ile Ser His Pro Asn

WO 00/12758

PCT/US99/19655

	325		330		335
Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln					
	340		345		350
Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn					
	355		360		365
Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp					
	370		375		380
Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala					
385		390		395	400
Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr					
	405		410		415
Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly					
	420		425		430
Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser					
	435		440		445
Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly					
	450		455		460
Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe					
465		470		475	480
Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly					
	485		490		